Overview

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

Status:
RECRUITING

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(PTS) in combination with or without first-line chemoimmunization based on standard treatment for stage IV driver gene-negative non-small cell lung cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Zhou Chengzhi

Treatments:

6-pyruvoyltetrahydropterin synthase